Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 1 |
2006 | 2 |
2007 | 1 |
2016 | 1 |
2017 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Anti-thrombotic technologies for medical devices.
Adv Drug Deliv Rev. 2017 Mar;112:2-11. doi: 10.1016/j.addr.2016.07.008. Epub 2016 Aug 3.
Adv Drug Deliv Rev. 2017.
PMID: 27496703
Review.
Antisense and RNAi: powerful tools in drug target discovery and validation.
Lavery KS, King TH.
Lavery KS, et al.
Curr Opin Drug Discov Devel. 2003 Jul;6(4):561-9.
Curr Opin Drug Discov Devel. 2003.
PMID: 12951819
Review.
Item in Clipboard
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.
Parker JC, et al. Among authors: lavery ks.
J Endocrinol. 2006 Oct;191(1):93-100. doi: 10.1677/joe.1.06904.
J Endocrinol. 2006.
PMID: 17065392
Item in Clipboard
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
Parker JC, Irwin N, Lavery KS, Green BD, O'Harte FP, Gault VA, Flatt PR.
Parker JC, et al. Among authors: lavery ks.
Biol Chem. 2007 Feb;388(2):221-6. doi: 10.1515/BC.2007.024.
Biol Chem. 2007.
PMID: 17261085
Item in Clipboard
Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
Green BD, et al. Among authors: lavery ks.
J Pharmacol Exp Ther. 2006 Aug;318(2):914-21. doi: 10.1124/jpet.105.097824. Epub 2006 Apr 28.
J Pharmacol Exp Ther. 2006.
PMID: 16648370
Item in Clipboard
Cite
Cite